Acute transverse myelitis in demyelinating disease of central nervous system
ICD-10 G37.3 is a billable code used to indicate a diagnosis of acute transverse myelitis in demyelinating disease of central nervous system.
Acute transverse myelitis (ATM) is an inflammatory condition affecting the spinal cord, characterized by the rapid onset of motor, sensory, and autonomic dysfunction. It is often associated with demyelinating diseases, particularly multiple sclerosis (MS). In ATM, the inflammation typically spans across a segment of the spinal cord, leading to symptoms such as weakness, sensory loss, and bladder dysfunction. The condition can occur as a distinct episode or as part of a broader demyelinating disease process. In the context of MS, ATM may present as a relapse, where patients experience a sudden worsening of neurological function. Diagnosis is primarily clinical, supported by MRI findings that reveal lesions in the spinal cord. Treatment often involves high-dose corticosteroids to reduce inflammation and immunomodulatory therapies to manage underlying demyelinating disease. Early intervention is crucial to improve outcomes and minimize long-term disability.
Detailed neurological examination findings, MRI results, and treatment plans.
Patients presenting with sudden onset of weakness, sensory changes, or bladder dysfunction.
Ensure clear documentation of the acute nature of symptoms and any prior history of demyelinating disease.
Functional assessments, rehabilitation goals, and progress notes.
Patients requiring rehabilitation post-ATM for mobility and function restoration.
Document the impact of ATM on daily activities and the need for assistive devices.
Used when a patient with acute transverse myelitis is admitted for evaluation and treatment.
Detailed history, examination findings, and medical decision-making.
Neurology specialists should ensure thorough documentation of neurological deficits.
The primary treatment for acute transverse myelitis typically involves high-dose corticosteroids to reduce inflammation. Immunomodulatory therapies may also be used to manage underlying demyelinating diseases.
